Cervical cancer in India: challenges and opportunities
Policy & Practice Report
MentAl Health Risk Factors among Older AdolesceNts living in Urban SluMs: An InTervention to Improve ResIlience (ANUMATI)
The adolescent population are the future of the country and in India they contribute to the demographic dividend of the nation. Adolescence is a vulnerable period with rapid changes in physical, mental and social levels. According to World Health Organisation, around 20% of children and adolescents suffer from a disabling mental illness, and suicide is the third leading cause of death among adolescents.
Hairdressers4Health
Background
Many health conditions are preventable if risk factors are identified early. Australian women have a high burden of modifiable risk factors including 60 percent being overweight or obese, and 20 percent having uncontrolled high blood pressure. Unfortunately there are many barriers that prevent women from visiting a health care professional and discussing their health. Hairdressers are one of the most common paid services used by Australian women, so hair salons present an opportunity to reach a large proportion of women. There is a clear need for novel approaches to engaging women on health issues, potentially including those that extend beyond traditional health care settings.
Aim
This study aims to understand the potential value of promoting women’s health outside traditional health care settings among female attendees at NSW hairdressing salons.
Design
The Hairdressers for Health study is a double-blind cluster-randomised controlled trial with a mixed-methods process evaluation.
The George Institute calls for improvements to government guide on serving sizes
Policy & Practice Report
Improving uptake for non-communicable disease screening: policy brief
Policy & Practice Report
The AustraLIan trial of GeNotype-guided pharmacothErapy for Depression (ALIGNED)
Background
Depression is a common form of mental distress that affects 1 in 7 Australians in their lifetime. People who are depressed not only feel depressed and sad, but often find they sleep poorly, experience a change in appetite, have low energy, poor concentration and have lowered self-esteem. Sometimes, they might think of harming themselves. Often, they find it hard to enjoy life or be productive.
Aim
This project seeks to investigate how pharmacogenomics can help to find the right antidepressant medication for people with depression.
Method
This is an investigator-initiated, randomised-controlled trial of pharmacogenomics-guided therapy versus standard care for people with moderate to severe depression.
Study participants are randomised to either the pharmacogenomics-guided intervention arm or a standard care (control) arm. The prescribing doctors of all participants are provided with a treatment guide to inform prescription of antidepressant therapy.
Potential Impact
Pharmacog
The George Institute calls for Equity to be at heart of the Australian Medical Research and Innovation Strategy and Priorities
Policy & Practice Report
Evaluation of Country of Origin Labelling for Food: Discussion Paper
Policy & Practice Report
Statin treatment for COVID-19 to optimise neurological recovery (STRONGER)
BACKGROUND
Statins are one of the most commonly prescribed medications globally to help control the body’s production of cholesterol, but they can also reduce the activity of certain cell proteins involved in the body’s response to infection and inflammation. COVID-19 infection puts patients at high risk of strokes from intense inflammation in the body, and from being critically ill. However, the effects of the virus may linger in the brain to disrupt pathways in more subtle ways that affects thinking, mood and sleep.
AIM
STRONGER aims to test whether treatment with a popular statin (atorvastatin), widely prescribed to prevent strokes and improve cardiovascular health, has anti-inflammatory effects that can improve memory and thinking after COVID-19 infection.
METHOD
STRONGER is an international randomised clinical trial of atorvastatin versus usual care to assess memory and brain function in 410 adults who have persistent neurological symptoms such as ‘brain fog’, headaches, poor
Digital marketing of breastmilk substitutes
Policy & Practice Report
SuSTAInX - Supporting Successful Transition to Adult belts In Cars: examining effectiveness of eXisting tools
Background Optimal crash protection requires the most appropriate restraint for a child’s size. For children ≥7 years of age, parents can choose whether they use seat belts or a booster seat. However, there is confusion about when children can safely use seat belts. The result is that many children >7 years inappropriately use seat belts, increasing risk of injury in a crash. There is existing information and advice aimed at helping parents to decide whether it is safe for their child to use an adult seat belt, however, they have not been tested for effectiveness.
Aims The overall aim of this study is to explore the information that parents need in order to make safe and correct decisions when it comes to restraining children using adult seat belts while travelling in a car. The data that we collect from this study will help us to develop easy-to-understand information resources and materials to support parents and help to reduce the level of incorrect use of adult seat belts
Comparing dialysis treatments for end-stage kidney disease (CONVINCE trial)
One in ten people worldwide have chronic kidney disease. Some of them progress to end-stage kidney disease (ESKD), which is when their kidney function falls below around 10% of normal. ESKD cannot be cured and people with the condition require either a kidney transplant or lifelong treatment with dialysis. Currently, haemodialysis is the most common form of dialysis used in the treatment of ESKD. However, it is not good at removing larger waste molecules from the blood and is often associated with a poor quality of life.
A large international multi-centre clinical trial (CONVINCE) investigated the superiority of an alternative dialysis treatment, haemodiafiltration, as compared to haemodialysis. Haemodiafiltration more effectively removes larger molecules that are accumulated, and was hypothesised to have better outcomes in terms of mortality, cardiovascular events, and quality of life.
The research team sought to determine the best treatment by conducting an international trial involving 1,36